Verified email-pattern data for Vectus Biosystems is currently limited. You can still use the company insights and contact sections below.
Vectus Biosystems Limited (ASX:VBS) is developing a treatment for fibrosis and high blood pressure, which includes the treatment for three of the largest diseases in the fibrotic market, namely heart, kidney and liver diseases. Vectus successfully completed its Initial Public Offering (IPO) on the Australian Securities Exchange (ASX:VBS) and commenced trading on ASX on 23 February 2016, after raising A$5.1 million. Funds from the IPO were predominantly used to develop the Company’s lead compound, VB0004, which aims to treat the hardening of functional tissue and high blood pressure. Vectus has conducted a range of successful pre-clinical trials, which have shown that VB0004 slows down the advances of fibrosis, potentially repairs damaged cell tissue and reduces high blood pressure. VB0004 is now progressing through a number of important milestones, including pharmaceutical scale-up and additional toxicity studies. Following successful results, the late 2019 convertible note fundraising, and the late 2020 share placement, the Company has funding for its Human Phase I trial. Vectus’ strategy is to develop and perform early validation of its drug candidates to the point where they may become commercially attractive to potential pharmaceutical partners.
The Company has also developed technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The technology, called Accugen, is owned by Vectus’ wholly-owned subsidiary Accugen Pty Limited. The technology offers a time, cost and accuracy benefit compared to currently-available systems.
The Company’s current stage of investment in Accugen is a commercialisation programme that may include direct sales, distribution partnerships and licensing opportunities.
Company Details
- Address
- 3-11 Primrose Avenue, Rosebery,nsw 2018,australia
- Industry
- Biotechnology Research
- Keywords
- Vesiculate.
- HQ
- Rosebery, NSW
Vectus Biosystems Questions
Vectus Biosystems's website is https://www.vectusbiosystems.com.au/
Vectus Biosystems's LinkedIn profile is https://au.linkedin.com/company/vectus-biosystems
Vectus Biosystems's industry is
Biotechnology Research
Vectus Biosystems's top competitors are
Vesiculate,
Acugen Lifesciences,
Venus Metals Corporation,
Vista Group International, Inc.,
Bluebird Capital,
Accugen Pty Ltd,
Vitrafy Life Sciences,
Us Masters Residential Property Fund,
Brainbankhq,
Visionflex.
Vectus Biosystems's categories are Biotechnology Research
Explore related pages
Related company profiles:
Free Chrome Extension
Find emails, phones & company data instantly
Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Aero Online
Your AI prospecting assistant
Select data to include:
Total price:
$0.00
0 records × $0.02 per record
How It Works
Get a Free Account
Sign up for a free account. No credit card required. Up to 10 free credits.
Search the #1 Contact Database
Get contact details of over 750M+ profiles across 60M companies – all with industry-leading accuracy. Sales Navigator and Recruiter users, try out our Email Finder Extension.
Use our AI-Powered Email Finder
Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.